After getting off its $100 million-plus IPO in the summer, gene editing biotech Intellia Therapeutics is getting ready for human tests of its preclinical…

Amryt, which is chaired by Shire founder Harry Stratford, has secured €20 million to fund a pivotal trial of its lead candidate in epidermolysis bullosa.

In this week's EuroBiotech Report, Kymab raises $100 million, AstraZeneca, Bicycle pen pact, Heptares to buy G7 and more.

Facebook and Napster billionaire Sean Parker has seen his Institute for Cancer Immunotherapy join forces with the Cancer Research Institute (CRI) to work on…

The House of Representatives has voted overwhelmingly to pass the 21st Century Cures Act, a contentious piece of legislation with implications for FDA.

AstraZeneca has penned a pact to develop bicyclic peptides with Bicycle Therapeutics.

CAR-T biotech Bluebird Bio has released topline data for its experimental med bb2121 in heavily pretreated multiple myeloma in a small, positive study that has…

OncoMed has posted early data on two antibodies for cancer, but investors are still focused on prospects for cancer stem cell drug tarextumab.

Biotech